Personalized Medicine in Otolaryngology and Head and Neck Surgery

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (5 December 2023) | Viewed by 1401

Special Issue Editors

1. Department of Anatomy and Experimental Oncology, Mons School of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium
2. Department of Otolaryngology-Head Neck Surgery, Elsan Polyclinic of Poitiers, Poitiers, France
Interests: otolaryngology; oral cancer oncology
Special Issues, Collections and Topics in MDPI journals
Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain
Interests: reconstruvtive surgery; molecular pathology; salivary gland; artificial intelligence; laryngeal cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine can predict the risk of underlying diseases through more accurate diagnosis, provide more effective and targeted treatment, and design the best treatment plan for patients, in order to maximize the therapeutic effect and minimize the side effects and even prevent the occurrence of diseases. New and personalized diagnostics and treatment innovations are necessary steps to improve the quality of treatment and quality of life for patients with otolaryngology–head and neck diseases.

This Special Issue is dedicated to personalized medicine in otolaryngology–head and neck surgery. All original research and review articles investigating personalized diagnostic and therapeutic approaches are welcome. Particular attention will be paid to papers that propose future management of patients considering the patients’ features, individualities, and new technologies.

Prof. Dr. Jerome Rene Lechien
Prof. Dr. Carlos M. Chiesa-Estomba
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized
  • medicine
  • therapeutic
  • treatment
  • diagnosis
  • surgery
  • otolaryngology
  • technology
  • diagnostic
  • medication

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 956 KiB  
Article
Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
by Takao Hamamoto, Yuki Sato, Kohei Yumii, Nobuyuki Chikuie, Takayuki Taruya, Yuichiro Horibe, Takashi Ishino, Tsutomu Ueda, Sachio Takeno and Kenichi Yoshimura
J. Pers. Med. 2023, 13(7), 1129; https://doi.org/10.3390/jpm13071129 - 12 Jul 2023
Cited by 3 | Viewed by 957
Abstract
Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for [...] Read more.
Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood-toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, TESS may be feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region during CRT. Although the precise mechanism of TESS on dysphagia remains unclear, its continued use has great potential for improving sensory disturbance. Full article
(This article belongs to the Special Issue Personalized Medicine in Otolaryngology and Head and Neck Surgery)
Show Figures

Figure 1

Back to TopTop